JP2022550640A5 - - Google Patents

Info

Publication number
JP2022550640A5
JP2022550640A5 JP2022546587A JP2022546587A JP2022550640A5 JP 2022550640 A5 JP2022550640 A5 JP 2022550640A5 JP 2022546587 A JP2022546587 A JP 2022546587A JP 2022546587 A JP2022546587 A JP 2022546587A JP 2022550640 A5 JP2022550640 A5 JP 2022550640A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
occurrence
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022546587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550640A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054347 external-priority patent/WO2021071802A1/en
Publication of JP2022550640A publication Critical patent/JP2022550640A/ja
Publication of JP2022550640A5 publication Critical patent/JP2022550640A5/ja
Priority to JP2025136895A priority Critical patent/JP2025186255A/ja
Withdrawn legal-status Critical Current

Links

JP2022546587A 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物 Withdrawn JP2022550640A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136895A JP2025186255A (ja) 2019-10-07 2025-08-20 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911670P 2019-10-07 2019-10-07
US62/911,670 2019-10-07
PCT/US2020/054347 WO2021071802A1 (en) 2019-10-07 2020-10-06 Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136895A Division JP2025186255A (ja) 2019-10-07 2025-08-20 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物

Publications (2)

Publication Number Publication Date
JP2022550640A JP2022550640A (ja) 2022-12-02
JP2022550640A5 true JP2022550640A5 (enExample) 2024-09-10

Family

ID=75438323

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022546587A Withdrawn JP2022550640A (ja) 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
JP2025136895A Pending JP2025186255A (ja) 2019-10-07 2025-08-20 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136895A Pending JP2025186255A (ja) 2019-10-07 2025-08-20 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物

Country Status (10)

Country Link
US (1) US20230026611A1 (enExample)
EP (1) EP4041407A4 (enExample)
JP (2) JP2022550640A (enExample)
KR (1) KR20220079882A (enExample)
CN (1) CN114746151A (enExample)
AU (1) AU2020362108A1 (enExample)
BR (1) BR112022006202A2 (enExample)
IL (1) IL291868A (enExample)
MX (1) MX2022004127A (enExample)
WO (1) WO2021071802A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
JP7716494B2 (ja) * 2021-03-30 2025-07-31 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
KR20240001192A (ko) * 2021-05-28 2024-01-03 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 스피로인돌리논 화합물
CN113637002B (zh) * 2021-08-02 2022-09-30 天津太平洋化学制药有限公司 一种尼拉帕尼的制备方法
CN113603573A (zh) * 2021-08-09 2021-11-05 苏州求索生物科技有限公司 一种3,5-二氯-2-碘苯甲醚的制备工艺
CN114213315A (zh) * 2021-12-31 2022-03-22 上海陶术生物科技有限公司 含氮杂环类化合物及其中间体的合成方法
CN114524800A (zh) * 2022-01-20 2022-05-24 上海陶术生物科技有限公司 尼拉帕尼中间体的合成方法
JP2026513122A (ja) * 2022-10-28 2026-04-23 上海深勢唯思科技有限責任公司 芳香族複素環式Ｋｖ１．３阻害剤、その製造方法及び用途
WO2025021167A1 (zh) * 2023-07-26 2025-01-30 上海汇伦医药股份有限公司 芳基含氮杂环化合物、药物组合物和应用
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途
WO2026021011A1 (zh) * 2024-07-26 2026-01-29 浙江海正药业股份有限公司 芳基三环类衍生物及其制备方法和用途
TW202607004A (zh) * 2024-08-01 2026-02-16 大陸商浙江海正藥業股份有限公司 ６，７－二氫－５Ｈ－吡咯並〔１，２ａ〕咪唑類衍生物及其製備方法和用途
TW202613099A (zh) * 2024-08-08 2026-04-01 大陸商上海美悅生物科技發展有限公司 取代的苯基化合物、及其藥物組合物和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2950479A1 (de) * 1979-12-14 1981-06-19 A. Nattermann & Cie GmbH, 5000 Köln N-(3-alkylamino-2-hydroxypropoxy-phenyl)-lactame, deren herstellungsverfahren und arzneimitttel auf deren basis
JPH07309837A (ja) * 1993-04-28 1995-11-28 Takeda Chem Ind Ltd ピリジン誘導体、その製造法および剤
JPH09278757A (ja) * 1996-04-15 1997-10-28 Takeda Chem Ind Ltd ヒドラゾン誘導体および剤
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
EP1056730A4 (en) * 1998-01-29 2003-01-02 Bristol Myers Squibb Co Diaryl-1,3,4-oxadiazolone benzoate
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AU2008307075B2 (en) * 2007-10-04 2012-05-17 Bionomics Limited Novel aryl potassium channel blockers and uses thereof
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
WO2011073269A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2017058716A1 (en) * 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
GB201610055D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610056D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
CN109705033B (zh) * 2019-01-22 2021-03-30 杭州壹瑞医药科技有限公司 N-杂芳基磺酰胺类衍生物及制备和应用

Similar Documents

Publication Publication Date Title
JP2022552445A5 (enExample)
JP2022551197A5 (enExample)
JP2023518286A5 (enExample)
JP2022550641A5 (enExample)
JP2022544714A5 (enExample)
JP2022551199A5 (enExample)
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
JP2020528889A5 (enExample)
JP7368365B2 (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法
JP2013530236A5 (enExample)
JP2019524883A5 (enExample)
JP2019519598A5 (enExample)
JP2021523200A5 (enExample)
JP2019514883A5 (enExample)
JP2007504128A5 (enExample)
JP2017530959A5 (enExample)
JP2021523225A5 (enExample)
JP2017512833A5 (enExample)
WO2015054960A1 (zh) 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
SK15892000A3 (sk) Spôsob syntézy cox-2 inhibítorov a medziprodukty
JP2025503448A5 (enExample)
JP2022065035A5 (enExample)
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
TW202345807A (zh) 基於二環丙基之il-17a調節劑及其用途
JP2024512931A5 (enExample)